TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from SynAct Pharma AB ( (SE:SYNACT) ).
SynAct Pharma AB released its interim report for the third quarter of 2025, highlighting significant events and financial developments. The report underscores the company’s ongoing research and development efforts in inflammatory diseases, which are crucial for its market positioning and stakeholder interests.
More about SynAct Pharma AB
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation through melanocortin biology.
Average Trading Volume: 179,014
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.14B
See more insights into SYNACT stock on TipRanks’ Stock Analysis page.